Investigational drug · Phase 3
Rese-cel
Also called: CABA-201
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Pemphigus Vulgaris, Systemic Sclerosis, Scleroderma.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "Rese-cel"
First trial start
2020
Sep 29, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Rese-cel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Pemphigus Vulgaris
- Systemic Sclerosis
- Scleroderma
- Interstitial Lung Diseases
- Generalized Myasthenia Gravis (gMG)
- Systemic Lupus Erythematosus
- Lupus Nephritis
Approved drugs for the same conditions: Myasthenia gravis · Lupus (SLE) · Neurology · Immunology and inflammation · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Rese-cel" as an intervention, largest first.
- RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory MyopathyPivotal-lookingRecruiting
Cabaletta BioIndustry
NCT06154252 · 74 participants (planned) · Start Dec 20, 2023 · Primary completion Jul 2028
Drug: CABA-201 following preconditioning with fludarabine and cyclophosphamide · For: Idiopathic Inflammatory Myopathy; Dermatomyositis; Anti-Synthetase Syndrome and 5 more
Sites: Orange, California; San Francisco, California; Aurora, Colorado · 38 sites in all
Cabaletta BioIndustry
NCT04422912 · 40 participants (planned) · Start Sep 29, 2020 · Primary completion Jan 2029
Drug: DSG3-CAART; CABA-201 · For: Pemphigus Vulgaris
Sites: Redwood City, California; Sacramento, California; New Haven, Connecticut · 13 sites in all
- RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic SclerosisPivotal-lookingRecruiting
Cabaletta BioIndustry
NCT06328777 · 37 participants (planned) · Start Jul 2, 2024 · Primary completion Jul 2029
Drug: CABA-201; CABA-201 · For: Systemic Sclerosis; Scleroderma; Interstitial Lung Diseases
Sites: New Haven, Connecticut; Jacksonville, Florida; Chicago, Illinois · 10 sites in all
Cabaletta BioIndustry
NCT07006805 · 0 participants · Start Jun 2026 · Primary completion Sep 2028
Drug: CABA-201 · For: Relapsing Multiple Sclerosis (RMS); Progressive Multiple Sclerosis (PMS); Multiple Sclerosis - Relapsing Remitting and 4 more
Newest research
PubMed records naming it or its code names, newest first.
- CD19 CAR T-cell therapy is feasible for patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial.
Nunez D, Stadanlick J, Furmanak T, et al. · Blood 2026
- Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial.
Nunez D, Volkov JR, Little C, et al. · Mol Ther Adv 2026
- Case study of CD19 CAR T therapy in a subject with immune-mediate necrotizing myopathy treated in the RESET-Myositis phase I/II trial.
Volkov J, Nunez D, Mozaffar T, et al. · Mol Ther 2024
- Preclinical specificity & activity of a fully human 41BB-expressing anti-CD19 CART- therapy for treatment-resistant autoimmune disease.
Peng BJ, Alvarado A, Cassim H, et al. · Mol Ther Methods Clin Dev 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.